K Szummer, et al.; Circ 2020; 142:1700-08

R Lopes, et al.; Circ 2020; 142:1725-35

ABBOTT PARK, Ill., Nov. 2, 2020 — Abbott today announced it has received CE Mark and approval in Australia for its new EnSite™ X EP System, and is launching the system throughout Europe and Australia. The EnSite X System is the only system that offers the option to navigate the cardiac anatomy two different ways on one platform. Abbott sought physician feedback to develop the EnSite X System to meet current needs as well as address emerging opportunities during cardiac ablation procedures. The new cardiac mapping platform builds upon the company’s electrophysiology portfolio and is designed to improve how physicians deliver ablation therapy to treat abnormal heart rhythms.

Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device

Stefan P. Schumacher | Wijnand J. Stuijfzand | Maksymilian P. Opolski | Albert C. van Rossum | Alexander Nap | Paul Knaapen

Alejandro Lemor | Seyed Hamed Hosseini Dehkordi | Mir B. Basir | Pedro A. Villablanca | Tarun Jain | Gerald C. Koenig | Khaldoon Alaswad | Jeffrey W. Moses | Navin K. Kapur | William O'Neill

Rhian E. Davies | Ian C. Gilchrist

Karim M. Al-Azizi | Amir S. Lotfi

Radiocontrast-induced acute kidney injury (RAKI) is a frequent complication during angiography and is associated with adverse prognosis. Most of the studies evaluating the long-term outcome of patients with RAKI are based on institutional registries. This is the first prospective study to evaluate the 5-year outcomes of patients with RAKI, and assess the effect of sodium bicarbonate (SB) in the long-term outcomes of patients with chronic kidney disease (CKD) undergoing non-emergent coronary angiography.

Transcatheter aortic valve replacement (TAVR) is currently an accepted therapeutic option for patients with severe symptomatic aortic stenosis. Initially approved for inoperable patients and those at high surgical risk, the indications have expanded for both intermediate and low-risk patients with excellent success rates and clinical data demonstrating excellent short and long-term outcomes.